Details of the Drug Combinations

General Information of This Drug (ID: DMCT3I8)

Drug Name

Ifosfamide DMCT3I8

Synonyms

Cyfos; Holoxan; Ifex; Ifosfamid; Ifosfamida; Ifosfamidum; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; Isosfamide; Mitoxana; Naxamide; Ifosfamide Sterile; Iso Endoxan; A 4942; ASTA Z 4942; Holoxan 1000; MJF 9325; Z 4942; Z4942; I-Phosphamide; IFEX (TN); Ifex (TN); Ifosfamida [INN-Spanish]; Ifosfamidum [INN-Latin]; Iphosphamid(e); Iso-Endoxan; MJF-9325; Mitoxana (TN); NPFAPI-04; Z-4942; Mitoxana, Ifex, Ifosfamide; Ifosfamide (JAN/USP/INN); Ifosfamide [USAN:INN:BAN:JAN]; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; (+-)-Ifosfamid; (+-)-Ifosphamide; (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; (D,L)-Ifosfamide; (R,S)-Ifosphamide; (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3,} 2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

Indication

Disease Entry	ICD 11	Status	REF
Adult central nervous system germ cell tumor	N.A.	Approved	[1]
Adult teratoma	N.A.	Approved	[1]
Advanced cancer	2A00-2F9Z	Approved	[1]
Extragonadal germ cell cancer	N.A.	Approved	[1]
Extragonadal germ cell tumor	N.A.	Approved	[1]
Kidney neoplasm	N.A.	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Testicular germ cell tumor	N.A.	Approved	[1]
Extragonadal nonseminomatous germ cell tumor	N.A.	Investigative	[1]
Extragonadal seminoma	N.A.	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]
Retinoblastoma	2D02.2	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

441 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABIRATERONE + Ifosfamide	DCGKXKA	ABIRATERONE	Papillary renal cell carcinoma (Cell Line: ACHN)	[3]
ABIRATERONE + Ifosfamide	DC8S5OC	ABIRATERONE	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
ABIRATERONE + Ifosfamide	DC73ZZI	ABIRATERONE	Renal cell carcinoma (Cell Line: SN12C)	[3]
ABIRATERONE + Ifosfamide	DCQEYRR	ABIRATERONE	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
ABIRATERONE + Ifosfamide	DCP7F16	ABIRATERONE	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
ABIRATERONE + Ifosfamide	DCZCQYT	ABIRATERONE	Melanoma (Cell Line: SK-MEL-2)	[5]
Altretamine + Ifosfamide	DCK9PR4	Altretamine	Adenocarcinoma (Cell Line: DU-145)	[3]
Altretamine + Ifosfamide	DC3RJ9E	Altretamine	Adenocarcinoma (Cell Line: NCIH23)	[3]
Altretamine + Ifosfamide	DCDN6FB	Altretamine	Adenocarcinoma (Cell Line: A549)	[3]
Altretamine + Ifosfamide	DCJY98F	Altretamine	Adenocarcinoma (Cell Line: HCT116)	[3]
Altretamine + Ifosfamide	DCJ6SLB	Altretamine	Adenocarcinoma (Cell Line: HT29)	[3]
Altretamine + Ifosfamide	DCSM6MJ	Altretamine	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[3]
Altretamine + Ifosfamide	DCB3QZI	Altretamine	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
Altretamine + Ifosfamide	DC0IMNH	Altretamine	Cutaneous melanoma (Cell Line: SK-MEL-28)	[3]
Altretamine + Ifosfamide	DCSKKCS	Altretamine	Cutaneous melanoma (Cell Line: SK-MEL-5)	[3]
Altretamine + Ifosfamide	DC9H68A	Altretamine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[3]
Altretamine + Ifosfamide	DCCPQDM	Altretamine	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Altretamine + Ifosfamide	DCPSR4T	Altretamine	Lung adenocarcinoma (Cell Line: EKVX)	[3]
Altretamine + Ifosfamide	DC8HOFR	Altretamine	Lung adenocarcinoma (Cell Line: NCI-H522)	[3]
Altretamine + Ifosfamide	DCFOEM2	Altretamine	Malignant melanoma (Cell Line: LOX IMVI)	[3]
Altretamine + Ifosfamide	DCW3BMS	Altretamine	Malignant melanoma (Cell Line: UACC62)	[3]
Altretamine + Ifosfamide	DCUPRSU	Altretamine	Melanoma (Cell Line: UACC-257)	[3]
Altretamine + Ifosfamide	DCWDGBD	Altretamine	Melanoma (Cell Line: SK-MEL-2)	[3]
Altretamine + Ifosfamide	DCMYCDX	Altretamine	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[3]
Altretamine + Ifosfamide	DCWGI3Z	Altretamine	Renal cell carcinoma (Cell Line: UO-31)	[3]
Altretamine + Ifosfamide	DCUDCAG	Altretamine	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Aminolevulinic Acid Hydrochloride + Ifosfamide	DC5CADG	Aminolevulinic Acid Hydrochloride	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[3]
Aminolevulinic Acid Hydrochloride + Ifosfamide	DC9HCIL	Aminolevulinic Acid Hydrochloride	Carcinoma (Cell Line: MCF7)	[4]
Aminolevulinic Acid Hydrochloride + Ifosfamide	DCBYFUS	Aminolevulinic Acid Hydrochloride	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[5]
Aminolevulinic Acid Hydrochloride + Ifosfamide	DC5ZKMV	Aminolevulinic Acid Hydrochloride	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Amonafide + Ifosfamide	DCQXNK7	Amonafide	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[3]
Amonafide + Ifosfamide	DCIXB1S	Amonafide	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Arfolitixorin + Ifosfamide	DCYTVLV	Arfolitixorin	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Arfolitixorin + Ifosfamide	DCQDZYY	Arfolitixorin	Adenocarcinoma (Cell Line: HCT116)	[5]
Bendamustine hydrochloride + Ifosfamide	DCRD57M	Bendamustine hydrochloride	Renal cell carcinoma (Cell Line: SN12C)	[3]
Bendamustine hydrochloride + Ifosfamide	DC2UD5R	Bendamustine hydrochloride	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Bendamustine hydrochloride + Ifosfamide	DCJ3BJT	Bendamustine hydrochloride	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Bendamustine hydrochloride + Ifosfamide	DCNGGM8	Bendamustine hydrochloride	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Bendamustine hydrochloride + Ifosfamide	DCPAVBZ	Bendamustine hydrochloride	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Bendamustine hydrochloride + Ifosfamide	DCNYAPN	Bendamustine hydrochloride	Malignant melanoma (Cell Line: UACC62)	[5]
Bendamustine hydrochloride + Ifosfamide	DCZJZHL	Bendamustine hydrochloride	Melanoma (Cell Line: UACC-257)	[5]
BIO-300 + Ifosfamide	DCL8NCK	BIO-300	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[3]
BIO-300 + Ifosfamide	DCT031J	BIO-300	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[3]
BIO-300 + Ifosfamide	DCTKX7Z	BIO-300	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
BIO-300 + Ifosfamide	DCDHL5Z	BIO-300	Glioma (Cell Line: SF-268)	[3]
BIO-300 + Ifosfamide	DCJ6PXR	BIO-300	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
BIO-300 + Ifosfamide	DCG4RIL	BIO-300	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
BIO-300 + Ifosfamide	DC694XT	BIO-300	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
BIO-300 + Ifosfamide	DCK9BM9	BIO-300	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
BIO-300 + Ifosfamide	DCY9GGF	BIO-300	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Bleomycin + Ifosfamide	DCXSGHJ	Bleomycin	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[3]
Bleomycin + Ifosfamide	DCD5VB9	Bleomycin	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Bleomycin + Ifosfamide	DC1JAA5	Bleomycin	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
Bleomycin + Ifosfamide	DC71275	Bleomycin	Adenocarcinoma (Cell Line: SW-620)	[5]
Bleomycin + Ifosfamide	DCZCGWF	Bleomycin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Busulfan + Ifosfamide	DCJ7PAJ	Busulfan	Adenocarcinoma (Cell Line: NCIH23)	[3]
Busulfan + Ifosfamide	DCK2VNA	Busulfan	Adenocarcinoma (Cell Line: HCC-2998)	[3]
Busulfan + Ifosfamide	DCU56O9	Busulfan	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Busulfan + Ifosfamide	DCX1U5N	Busulfan	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[3]
Cabazitaxel + Ifosfamide	DCA2YYS	Cabazitaxel	Melanoma (Cell Line: UACC-257)	[3]
Chlorambucil + Ifosfamide	DCUJFEI	Chlorambucil	Adenocarcinoma (Cell Line: NCIH23)	[3]
Chlorambucil + Ifosfamide	DCMV2ML	Chlorambucil	Adenocarcinoma (Cell Line: HCC-2998)	[3]
Chlorambucil + Ifosfamide	DCHY6MU	Chlorambucil	Adenocarcinoma (Cell Line: HT29)	[3]
Chlorambucil + Ifosfamide	DC4QRQ0	Chlorambucil	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[3]
Chlorambucil + Ifosfamide	DCQGMDZ	Chlorambucil	Amelanotic melanoma (Cell Line: MDA-MB-435)	[3]
Chlorambucil + Ifosfamide	DCJUCIC	Chlorambucil	Clear cell renal cell carcinoma (Cell Line: 786-0)	[3]
Chlorambucil + Ifosfamide	DCUETCM	Chlorambucil	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
Chlorambucil + Ifosfamide	DCZF8NT	Chlorambucil	Glioma (Cell Line: SF-539)	[3]
Chlorambucil + Ifosfamide	DC52SWE	Chlorambucil	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[3]
Chlorambucil + Ifosfamide	DCIUCWV	Chlorambucil	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Chlorambucil + Ifosfamide	DCW54O5	Chlorambucil	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Crizotinib + Ifosfamide	DCTT74M	Crizotinib	Adenocarcinoma (Cell Line: OVCAR3)	[3]
Crizotinib + Ifosfamide	DC01E1V	Crizotinib	Clear cell renal cell carcinoma (Cell Line: 786-0)	[3]
Crizotinib + Ifosfamide	DC12ECP	Crizotinib	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Crizotinib + Ifosfamide	DCDE5KD	Crizotinib	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Cyclophosphamide + Ifosfamide	DCNXQ72	Cyclophosphamide	Adenocarcinoma (Cell Line: NCIH23)	[3]
Cyclophosphamide + Ifosfamide	DC0CBTH	Cyclophosphamide	Adenocarcinoma (Cell Line: A549)	[3]
Cyclophosphamide + Ifosfamide	DCO6I23	Cyclophosphamide	Adenocarcinoma (Cell Line: HT29)	[3]
Cyclophosphamide + Ifosfamide	DCWKYRI	Cyclophosphamide	Adenocarcinoma (Cell Line: HCT116)	[3]
Cyclophosphamide + Ifosfamide	DCKIPGE	Cyclophosphamide	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[3]
Cyclophosphamide + Ifosfamide	DCIPPO8	Cyclophosphamide	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[3]
Cyclophosphamide + Ifosfamide	DCWTZ82	Cyclophosphamide	Amelanotic melanoma (Cell Line: MDA-MB-435)	[3]
Cyclophosphamide + Ifosfamide	DC3SLXE	Cyclophosphamide	Anaplastic large cell lymphoma (Cell Line: SR)	[3]
Cyclophosphamide + Ifosfamide	DC7S7Z1	Cyclophosphamide	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Cyclophosphamide + Ifosfamide	DCZ0JUE	Cyclophosphamide	Cutaneous melanoma (Cell Line: SK-MEL-28)	[3]
Cyclophosphamide + Ifosfamide	DCFNU74	Cyclophosphamide	Glioma (Cell Line: SF-295)	[3]
Cyclophosphamide + Ifosfamide	DCY1AFS	Cyclophosphamide	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[3]
Cyclophosphamide + Ifosfamide	DC3KMH5	Cyclophosphamide	Lung adenocarcinoma (Cell Line: HOP-62)	[3]
Cyclophosphamide + Ifosfamide	DCIKZP7	Cyclophosphamide	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[3]
Cyclophosphamide + Ifosfamide	DC2FO8C	Cyclophosphamide	Malignant melanoma (Cell Line: LOX IMVI)	[3]
Cyclophosphamide + Ifosfamide	DCW1A6L	Cyclophosphamide	Melanoma (Cell Line: SK-MEL-2)	[3]
Cyclophosphamide + Ifosfamide	DCMOIEM	Cyclophosphamide	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Cyclophosphamide + Ifosfamide	DCZAMKO	Cyclophosphamide	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
Cyclophosphamide + Ifosfamide	DC9IF58	Cyclophosphamide	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Dactinomycin + Ifosfamide	DCY27HQ	Dactinomycin	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Dactinomycin + Ifosfamide	DCV1VM2	Dactinomycin	Adenocarcinoma (Cell Line: DU-145)	[5]
Dactinomycin + Ifosfamide	DC5OZJ7	Dactinomycin	Adenocarcinoma (Cell Line: A549)	[5]
Dactinomycin + Ifosfamide	DC38R2A	Dactinomycin	Adenocarcinoma (Cell Line: HCT-15)	[5]
Dactinomycin + Ifosfamide	DCNAAPY	Dactinomycin	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[5]
Dactinomycin + Ifosfamide	DC8CCJW	Dactinomycin	Astrocytoma (Cell Line: SNB-19)	[5]
Dactinomycin + Ifosfamide	DCO6L5W	Dactinomycin	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Dactinomycin + Ifosfamide	DC3G96U	Dactinomycin	Prostate carcinoma (Cell Line: PC-3)	[5]
Dactinomycin + Ifosfamide	DCU25M1	Dactinomycin	Renal cell carcinoma (Cell Line: UO-31)	[5]
Dasatinib + Ifosfamide	DCEUMWU	Dasatinib	Adenocarcinoma (Cell Line: HCT116)	[3]
Dasatinib + Ifosfamide	DCFF413	Dasatinib	Amelanotic melanoma (Cell Line: M14)	[3]
Dasatinib + Ifosfamide	DCLARUI	Dasatinib	Glioma (Cell Line: SF-295)	[3]
Dasatinib + Ifosfamide	DCV75TB	Dasatinib	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[3]
Dexrazoxane + Ifosfamide	DCW1NRL	Dexrazoxane	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[3]
Dexrazoxane + Ifosfamide	DC8LFP1	Dexrazoxane	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Dexrazoxane + Ifosfamide	DC4RZK9	Dexrazoxane	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Dexrazoxane + Ifosfamide	DCSFKJ5	Dexrazoxane	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Dexrazoxane + Ifosfamide	DCDFI7C	Dexrazoxane	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Dexrazoxane + Ifosfamide	DCDQK9O	Dexrazoxane	Adenocarcinoma (Cell Line: HCT116)	[5]
Dexrazoxane + Ifosfamide	DCEOD44	Dexrazoxane	Adenocarcinoma (Cell Line: HT29)	[5]
Dexrazoxane + Ifosfamide	DC9QFPU	Dexrazoxane	Melanoma (Cell Line: UACC-257)	[5]
Dexrazoxane + Ifosfamide	DCOV65W	Dexrazoxane	Melanoma (Cell Line: SK-MEL-2)	[5]
DFN-15 + Ifosfamide	DCY4GA0	DFN-15	Astrocytoma (Cell Line: U251)	[3]
DFN-15 + Ifosfamide	DCPJ7HL	DFN-15	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
DFN-15 + Ifosfamide	DCMK81K	DFN-15	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
DFN-15 + Ifosfamide	DCEFAU9	DFN-15	Adenocarcinoma (Cell Line: OVCAR3)	[5]
DFN-15 + Ifosfamide	DCPKT00	DFN-15	Adenocarcinoma (Cell Line: HT29)	[5]
DFN-15 + Ifosfamide	DCGK0PH	DFN-15	Adenocarcinoma (Cell Line: HCT116)	[5]
DFN-15 + Ifosfamide	DCSLUH0	DFN-15	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
DFN-15 + Ifosfamide	DCYGLT9	DFN-15	Melanoma (Cell Line: SK-MEL-2)	[5]
Digitoxin + Ifosfamide	DCLF1JC	Digitoxin	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Digitoxin + Ifosfamide	DCUD92W	Digitoxin	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[3]
Docetaxel + Ifosfamide	DCVSPZF	Docetaxel	Adenocarcinoma (Cell Line: OVCAR3)	[3]
Docetaxel + Ifosfamide	DCDN1H2	Docetaxel	Adenocarcinoma (Cell Line: HCT116)	[3]
Docetaxel + Ifosfamide	DC8A0UW	Docetaxel	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Docetaxel + Ifosfamide	DC0IA3B	Docetaxel	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[3]
Docetaxel + Ifosfamide	DCGNNY3	Docetaxel	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Docetaxel + Ifosfamide	DCJSI7X	Docetaxel	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[3]
Docetaxel + Ifosfamide	DCI9AOA	Docetaxel	Renal cell carcinoma (Cell Line: SN12C)	[3]
Epirubicin + Ifosfamide	DC681NW	Epirubicin	Anaplastic large cell lymphoma (Cell Line: SR)	[3]
Epirubicin + Ifosfamide	DC5GJ53	Epirubicin	Clear cell renal cell carcinoma (Cell Line: 786-0)	[3]
Epirubicin + Ifosfamide	DCOETNI	Epirubicin	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
Epirubicin + Ifosfamide	DC1YDML	Epirubicin	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Epirubicin + Ifosfamide	DCTMHOE	Epirubicin	Renal cell carcinoma (Cell Line: SN12C)	[3]
Epirubicin + Ifosfamide	DCUB46B	Epirubicin	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
Epirubicin + Ifosfamide	DC3SQX1	Epirubicin	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Epirubicin + Ifosfamide	DC1YBDK	Epirubicin	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Epirubicin + Ifosfamide	DC8W80C	Epirubicin	Adenocarcinoma (Cell Line: HCT116)	[5]
Epirubicin + Ifosfamide	DCXBPVP	Epirubicin	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Epirubicin + Ifosfamide	DC8N4FO	Epirubicin	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
ER819762 + Ifosfamide	DCL7BJD	ER819762	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
ER819762 + Ifosfamide	DC0O34S	ER819762	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
ER819762 + Ifosfamide	DCQ08T1	ER819762	Adenocarcinoma (Cell Line: DU-145)	[5]
ER819762 + Ifosfamide	DC1R05V	ER819762	Prostate carcinoma (Cell Line: PC-3)	[5]
Estramustine + Ifosfamide	DC6RK4Z	Estramustine	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Estramustine + Ifosfamide	DCHS51B	Estramustine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
FORMESTANE + Ifosfamide	DCYLU8X	FORMESTANE	Adenocarcinoma (Cell Line: DU-145)	[3]
FORMESTANE + Ifosfamide	DC323FP	FORMESTANE	Adenocarcinoma (Cell Line: NCIH23)	[3]
FORMESTANE + Ifosfamide	DCHM719	FORMESTANE	Adenocarcinoma (Cell Line: HCT116)	[3]
FORMESTANE + Ifosfamide	DCD13RS	FORMESTANE	Glioma (Cell Line: SF-539)	[3]
FORMESTANE + Ifosfamide	DCF6JYT	FORMESTANE	Melanoma (Cell Line: SK-MEL-2)	[3]
FORMESTANE + Ifosfamide	DCODJVW	FORMESTANE	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
FORMESTANE + Ifosfamide	DCCDHI7	FORMESTANE	Prostate carcinoma (Cell Line: PC-3)	[3]
Fulvestrant + Ifosfamide	DC0993L	Fulvestrant	Adenocarcinoma (Cell Line: OVCAR3)	[3]
Fulvestrant + Ifosfamide	DCI0BTZ	Fulvestrant	Adenocarcinoma (Cell Line: HCT116)	[3]
Fulvestrant + Ifosfamide	DC1JNLF	Fulvestrant	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Fulvestrant + Ifosfamide	DCIU1Z1	Fulvestrant	Cutaneous melanoma (Cell Line: SK-MEL-5)	[3]
Fulvestrant + Ifosfamide	DCEJVOS	Fulvestrant	Glioma (Cell Line: SF-268)	[3]
Fulvestrant + Ifosfamide	DCNECO5	Fulvestrant	Lung adenocarcinoma (Cell Line: HOP-62)	[3]
Fulvestrant + Ifosfamide	DCWQ8HM	Fulvestrant	Melanoma (Cell Line: SK-MEL-2)	[3]
Gefitinib + Ifosfamide	DCTR6GQ	Gefitinib	Glioma (Cell Line: SF-268)	[3]
Hepzato + Ifosfamide	DCMPL9G	Hepzato	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Hepzato + Ifosfamide	DCOQZGW	Hepzato	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Hepzato + Ifosfamide	DC6UKK3	Hepzato	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Idarubicin + Ifosfamide	DCGXA64	Idarubicin	Astrocytoma (Cell Line: U251)	[3]
Idarubicin + Ifosfamide	DCJAKTX	Idarubicin	Clear cell renal cell carcinoma (Cell Line: 786-0)	[3]
Idarubicin + Ifosfamide	DCT5CKV	Idarubicin	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Idarubicin + Ifosfamide	DCYRPNB	Idarubicin	Adenocarcinoma (Cell Line: DU-145)	[5]
Idarubicin + Ifosfamide	DCQ5Z2Q	Idarubicin	Adenocarcinoma (Cell Line: HCT-15)	[5]
Idarubicin + Ifosfamide	DCSLO6B	Idarubicin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[5]
Idarubicin + Ifosfamide	DC6D8CO	Idarubicin	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Idarubicin + Ifosfamide	DCDGOLB	Idarubicin	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Ifosfamide + Pentostatin	DCG6QNA	Pentostatin	Anaplastic large cell lymphoma (Cell Line: SR)	[3]
Ifosfamide + Ixabepilone	DCO1CGS	Ixabepilone	Melanoma (Cell Line: MALME-3M)	[3]
Ifosfamide + Arsenic trioxide	DCZ3VEU	Arsenic trioxide	Malignant melanoma (Cell Line: LOX IMVI)	[3]
Ifosfamide + Bortezomib	DCQ6OJ6	Bortezomib	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[3]
Ifosfamide + Bortezomib	DCA44Z6	Bortezomib	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Ifosfamide + Bortezomib	DCJP3OF	Bortezomib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[3]
Ifosfamide + Pentostatin	DCBY4IZ	Pentostatin	Carcinoma (Cell Line: MCF7)	[4]
Ifosfamide + Pentostatin	DCSBAKQ	Pentostatin	Colon carcinoma (Cell Line: KM12)	[4]
Ifosfamide + Ixabepilone	DCMVQFY	Ixabepilone	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Imatinib + Ifosfamide	DC8VT0U	Imatinib	Adenocarcinoma (Cell Line: OVCAR3)	[3]
Imatinib + Ifosfamide	DC5K5Y7	Imatinib	Adenocarcinoma (Cell Line: HCT116)	[3]
Imatinib + Ifosfamide	DC70N9C	Imatinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[3]
Imatinib + Ifosfamide	DCCNPLA	Imatinib	Lung adenocarcinoma (Cell Line: HOP-62)	[3]
Imatinib + Ifosfamide	DCO2LBS	Imatinib	Non-small cell lung carcinoma (Cell Line: HOP-92)	[3]
Imatinib + Ifosfamide	DCZU18J	Imatinib	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Indazole derivative 5 + Ifosfamide	DCOM71C	Indazole derivative 5	Clear cell renal cell carcinoma (Cell Line: 786-0)	[3]
Indazole derivative 5 + Ifosfamide	DCCLB8U	Indazole derivative 5	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Indazole derivative 5 + Ifosfamide	DCUO996	Indazole derivative 5	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Indazole derivative 5 + Ifosfamide	DCSPK7E	Indazole derivative 5	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
Indazole derivative 5 + Ifosfamide	DCY8BSD	Indazole derivative 5	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Indazole derivative 5 + Ifosfamide	DCY9FO1	Indazole derivative 5	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Indazole derivative 5 + Ifosfamide	DCJEQF5	Indazole derivative 5	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Indazole derivative 5 + Ifosfamide	DCJWLG0	Indazole derivative 5	Adenocarcinoma (Cell Line: NCIH23)	[5]
Indazole derivative 5 + Ifosfamide	DCW0QXX	Indazole derivative 5	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Indazole derivative 5 + Ifosfamide	DCNTV10	Indazole derivative 5	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Indazole derivative 5 + Ifosfamide	DCRZMV0	Indazole derivative 5	Melanoma (Cell Line: UACC-257)	[5]
Indazole derivative 5 + Ifosfamide	DCKYPVY	Indazole derivative 5	Melanoma (Cell Line: SK-MEL-2)	[5]
Indazole derivative 5 + Ifosfamide	DCK4Z2Z	Indazole derivative 5	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Indazole derivative 5 + Ifosfamide	DC051KL	Indazole derivative 5	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Isoniazid + Ifosfamide	DCLVNF3	Isoniazid	Adenocarcinoma (Cell Line: A549)	[3]
Isoniazid + Ifosfamide	DCPIP3S	Isoniazid	Adenocarcinoma (Cell Line: HCT116)	[3]
Isoniazid + Ifosfamide	DCW9DRG	Isoniazid	Adenocarcinoma (Cell Line: HT29)	[3]
Isoniazid + Ifosfamide	DC43S33	Isoniazid	Anaplastic large cell lymphoma (Cell Line: SR)	[3]
Isoniazid + Ifosfamide	DCNQFXT	Isoniazid	Lung adenocarcinoma (Cell Line: HOP-62)	[3]
Isoniazid + Ifosfamide	DC2J8N7	Isoniazid	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[3]
Isoniazid + Ifosfamide	DC2TJ3M	Isoniazid	Melanoma (Cell Line: SK-MEL-2)	[3]
Lapatinib + Ifosfamide	DCZ60GD	Lapatinib	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Lapatinib + Ifosfamide	DCG8XU8	Lapatinib	Adenocarcinoma (Cell Line: HT29)	[5]
Lapatinib + Ifosfamide	DC22N8K	Lapatinib	Amelanotic melanoma (Cell Line: M14)	[5]
Lapatinib + Ifosfamide	DC5JK9I	Lapatinib	Glioma (Cell Line: SF-295)	[5]
Lapatinib + Ifosfamide	DC5NISX	Lapatinib	Glioma (Cell Line: SF-539)	[5]
Lapatinib + Ifosfamide	DCX2GME	Lapatinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[5]
Lapatinib + Ifosfamide	DCTHPEN	Lapatinib	Prostate carcinoma (Cell Line: PC-3)	[5]
Lenalidomide + Ifosfamide	DCG0K2E	Lenalidomide	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Lenalidomide + Ifosfamide	DC11VQS	Lenalidomide	Renal cell carcinoma (Cell Line: UO-31)	[3]
Letrozole + Ifosfamide	DC4IC79	Letrozole	Adenocarcinoma (Cell Line: NCIH23)	[3]
Letrozole + Ifosfamide	DCR1JC7	Letrozole	Adenocarcinoma (Cell Line: SW-620)	[3]
Letrozole + Ifosfamide	DCSIZSO	Letrozole	Adenocarcinoma (Cell Line: HCT116)	[3]
Letrozole + Ifosfamide	DC7ONVS	Letrozole	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Letrozole + Ifosfamide	DC754VJ	Letrozole	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
Letrozole + Ifosfamide	DCGM5X2	Letrozole	Lung adenocarcinoma (Cell Line: EKVX)	[3]
Letrozole + Ifosfamide	DC5E5N0	Letrozole	Prostate carcinoma (Cell Line: PC-3)	[3]
Letrozole + Ifosfamide	DCYH69N	Letrozole	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Mechlorethamine + Ifosfamide	DC7ORA7	Mechlorethamine	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[3]
Mechlorethamine + Ifosfamide	DC3TE8X	Mechlorethamine	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[3]
Mechlorethamine + Ifosfamide	DCIFBII	Mechlorethamine	Anaplastic large cell lymphoma (Cell Line: SR)	[3]
Mechlorethamine + Ifosfamide	DCDS1DV	Mechlorethamine	Astrocytoma (Cell Line: SNB-19)	[3]
Mechlorethamine + Ifosfamide	DC9XPRB	Mechlorethamine	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[3]
Mechlorethamine + Ifosfamide	DC812A6	Mechlorethamine	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
Mechlorethamine + Ifosfamide	DC7G7RL	Mechlorethamine	Clear cell renal cell carcinoma (Cell Line: 786-0)	[3]
Mechlorethamine + Ifosfamide	DC5S3AR	Mechlorethamine	Glioma (Cell Line: SF-268)	[3]
Mechlorethamine + Ifosfamide	DCPIKPQ	Mechlorethamine	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Mechlorethamine + Ifosfamide	DCS6G7J	Mechlorethamine	Renal cell carcinoma (Cell Line: SN12C)	[3]
Mechlorethamine + Ifosfamide	DCZJOO4	Mechlorethamine	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Mechlorethamine + Ifosfamide	DCFB62O	Mechlorethamine	Carcinoma (Cell Line: MCF7)	[4]
Mechlorethamine + Ifosfamide	DC3ZJRA	Mechlorethamine	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
Mechlorethamine + Ifosfamide	DCM8BP0	Mechlorethamine	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Mechlorethamine + Ifosfamide	DCO4KI0	Mechlorethamine	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Mechlorethamine + Ifosfamide	DC1S2M8	Mechlorethamine	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Mechlorethamine + Ifosfamide	DCOLGI2	Mechlorethamine	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Mechlorethamine + Ifosfamide	DC9IPPM	Mechlorethamine	Adenocarcinoma (Cell Line: SW-620)	[5]
Mechlorethamine + Ifosfamide	DCD0SA6	Mechlorethamine	Adenocarcinoma (Cell Line: HT29)	[5]
Mechlorethamine + Ifosfamide	DCGWPB6	Mechlorethamine	Adenocarcinoma (Cell Line: HCT116)	[5]
Mechlorethamine + Ifosfamide	DCYG3JI	Mechlorethamine	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Mechlorethamine + Ifosfamide	DCQG6VO	Mechlorethamine	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Mechlorethamine + Ifosfamide	DCAIJAZ	Mechlorethamine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Mechlorethamine + Ifosfamide	DCO4N2X	Mechlorethamine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Mechlorethamine + Ifosfamide	DCM3Y5V	Mechlorethamine	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Mechlorethamine + Ifosfamide	DC3YUU8	Mechlorethamine	Malignant melanoma (Cell Line: UACC62)	[5]
Mechlorethamine + Ifosfamide	DCFMO62	Mechlorethamine	Melanoma (Cell Line: UACC-257)	[5]
Mechlorethamine + Ifosfamide	DCKCEYF	Mechlorethamine	Melanoma (Cell Line: SK-MEL-2)	[5]
Mechlorethamine + Ifosfamide	DCQ57DE	Mechlorethamine	Melanoma (Cell Line: MALME-3M)	[5]
Mepacrine + Ifosfamide	DCWXFJP	Mepacrine	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[3]
Mercaptopurine + Ifosfamide	DCQNSFW	Mercaptopurine	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Methotrexate + Ifosfamide	DCHCKYT	Methotrexate	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Mitomycin + Ifosfamide	DC8OY4T	Mitomycin	Anaplastic large cell lymphoma (Cell Line: SR)	[3]
Mitomycin + Ifosfamide	DCXSYTV	Mitomycin	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Mitomycin + Ifosfamide	DCESEPH	Mitomycin	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
Mitomycin + Ifosfamide	DCK82K4	Mitomycin	Carcinoma (Cell Line: MCF7)	[4]
Mitomycin + Ifosfamide	DC7JXP6	Mitomycin	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Mitomycin + Ifosfamide	DCCSSLT	Mitomycin	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Mitomycin + Ifosfamide	DCO5JR1	Mitomycin	Adenocarcinoma (Cell Line: DU-145)	[5]
Mitomycin + Ifosfamide	DCPXCMG	Mitomycin	Adenocarcinoma (Cell Line: HT29)	[5]
Mitomycin + Ifosfamide	DCZO39Y	Mitomycin	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Mitomycin + Ifosfamide	DCT8WQ6	Mitomycin	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Nilotinib + Ifosfamide	DCSITCJ	Nilotinib	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Nilotinib + Ifosfamide	DCVDOCL	Nilotinib	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Nilotinib + Ifosfamide	DCWFZ6G	Nilotinib	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Nilotinib + Ifosfamide	DCF9ZOF	Nilotinib	Melanoma (Cell Line: SK-MEL-2)	[5]
Nilotinib + Ifosfamide	DCXZU8A	Nilotinib	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Picoplatin + Ifosfamide	DCPIP5S	Picoplatin	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Picoplatin + Ifosfamide	DC3R2ND	Picoplatin	Carcinoma (Cell Line: RXF 393)	[4]
Picoplatin + Ifosfamide	DCNJD3T	Picoplatin	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
Picoplatin + Ifosfamide	DCUV9BR	Picoplatin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Plicamycin + Ifosfamide	DCLOLGG	Plicamycin	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Plicamycin + Ifosfamide	DC9M83Y	Plicamycin	Clear cell renal cell carcinoma (Cell Line: A498)	[3]
Plicamycin + Ifosfamide	DCK3J4F	Plicamycin	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[3]
Plicamycin + Ifosfamide	DC0ZAZG	Plicamycin	Adenocarcinoma (Cell Line: DU-145)	[5]
Plicamycin + Ifosfamide	DC9ERDN	Plicamycin	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Plicamycin + Ifosfamide	DCYWSSY	Plicamycin	Adenocarcinoma (Cell Line: HCT116)	[5]
Plicamycin + Ifosfamide	DCK1VQW	Plicamycin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Plicamycin + Ifosfamide	DC1N3G8	Plicamycin	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Plicamycin + Ifosfamide	DCAWZ68	Plicamycin	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Plicamycin + Ifosfamide	DC7JI7Q	Plicamycin	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
PMID28460551-Compound-2 + Ifosfamide	DCP8ZW9	PMID28460551-Compound-2	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
PMID28460551-Compound-2 + Ifosfamide	DCHOUFX	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: HCT-15)	[5]
PMID28460551-Compound-2 + Ifosfamide	DC8C60L	PMID28460551-Compound-2	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
PMID28870136-Compound-43 + Ifosfamide	DCQHKW0	PMID28870136-Compound-43	Colon carcinoma (Cell Line: KM12)	[4]
PMID28870136-Compound-43 + Ifosfamide	DC7OLAZ	PMID28870136-Compound-43	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
PMID28870136-Compound-43 + Ifosfamide	DCTI6IN	PMID28870136-Compound-43	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Pomalidomide + Ifosfamide	DCZPIRI	Pomalidomide	Adenocarcinoma (Cell Line: A549)	[3]
Pomalidomide + Ifosfamide	DC9ITFC	Pomalidomide	Adenocarcinoma (Cell Line: HT29)	[3]
Pomalidomide + Ifosfamide	DCW7NDN	Pomalidomide	Adenocarcinoma (Cell Line: HCT116)	[3]
Pomalidomide + Ifosfamide	DCGCG7G	Pomalidomide	Cutaneous melanoma (Cell Line: SK-MEL-28)	[3]
Pomalidomide + Ifosfamide	DC5KGQ7	Pomalidomide	Lung adenocarcinoma (Cell Line: HOP-62)	[3]
Pomalidomide + Ifosfamide	DC8Q9HP	Pomalidomide	Malignant melanoma (Cell Line: LOX IMVI)	[3]
Pomalidomide + Ifosfamide	DCMCMKM	Pomalidomide	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Pralatrexate + Ifosfamide	DC65S39	Pralatrexate	Adenocarcinoma (Cell Line: NCIH23)	[5]
Pralatrexate + Ifosfamide	DCJLJZC	Pralatrexate	Melanoma (Cell Line: SK-MEL-2)	[5]
Pralatrexate + Ifosfamide	DCOHDUE	Pralatrexate	Melanoma (Cell Line: UACC-257)	[5]
Raloxifene + Ifosfamide	DC67GNF	Raloxifene	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[3]
Raloxifene + Ifosfamide	DCICGSU	Raloxifene	Anaplastic large cell lymphoma (Cell Line: SR)	[3]
Raloxifene + Ifosfamide	DCENSKS	Raloxifene	Astrocytoma (Cell Line: SNB-19)	[3]
Raloxifene + Ifosfamide	DCPINZB	Raloxifene	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Raloxifene + Ifosfamide	DCR1KFH	Raloxifene	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
Raloxifene + Ifosfamide	DCYHWRT	Raloxifene	Clear cell renal cell carcinoma (Cell Line: 786-0)	[3]
Raloxifene + Ifosfamide	DC9Z621	Raloxifene	Glioma (Cell Line: SF-268)	[3]
Raloxifene + Ifosfamide	DCP8FIE	Raloxifene	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Raloxifene + Ifosfamide	DCXDFBZ	Raloxifene	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Raloxifene + Ifosfamide	DCLVL4O	Raloxifene	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
Raloxifene + Ifosfamide	DC9VYK9	Raloxifene	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Raloxifene + Ifosfamide	DCIT81F	Raloxifene	Adenocarcinoma (Cell Line: DU-145)	[5]
Raloxifene + Ifosfamide	DCG77E4	Raloxifene	Adenocarcinoma (Cell Line: HCT116)	[5]
Raloxifene + Ifosfamide	DC6RUXR	Raloxifene	Adenocarcinoma (Cell Line: SW-620)	[5]
Raloxifene + Ifosfamide	DCQCYY8	Raloxifene	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Raloxifene + Ifosfamide	DCQPU55	Raloxifene	Adenocarcinoma (Cell Line: HT29)	[5]
Raloxifene + Ifosfamide	DC1GM88	Raloxifene	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Raloxifene + Ifosfamide	DCC63OX	Raloxifene	Amelanotic melanoma (Cell Line: M14)	[5]
Raloxifene + Ifosfamide	DCRKYDE	Raloxifene	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Raloxifene + Ifosfamide	DCCOR2A	Raloxifene	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Raloxifene + Ifosfamide	DC0OWKT	Raloxifene	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Raloxifene + Ifosfamide	DCHO11L	Raloxifene	Melanoma (Cell Line: SK-MEL-2)	[5]
Raloxifene + Ifosfamide	DCRLZ4X	Raloxifene	Melanoma (Cell Line: UACC-257)	[5]
Raloxifene + Ifosfamide	DC14ZJE	Raloxifene	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Raloxifene + Ifosfamide	DCQ27RI	Raloxifene	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Raloxifene + Ifosfamide	DC5QW4S	Raloxifene	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Ruxolitinib + Ifosfamide	DCVOMA8	Ruxolitinib	Clear cell renal cell carcinoma (Cell Line: 786-0)	[3]
Ruxolitinib + Ifosfamide	DC2080A	Ruxolitinib	Glioma (Cell Line: SF-268)	[3]
Ruxolitinib + Ifosfamide	DCOWOMQ	Ruxolitinib	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Ruxolitinib + Ifosfamide	DCZ4OHV	Ruxolitinib	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Ruxolitinib + Ifosfamide	DC8FZV4	Ruxolitinib	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
SCH 727965 + Ifosfamide	DC5HO05	SCH 727965	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Sirolimus + Ifosfamide	DCUQ49T	Sirolimus	Renal cell carcinoma (Cell Line: SN12C)	[3]
Sirolimus + Ifosfamide	DCXBLDW	Sirolimus	Carcinoma (Cell Line: RXF 393)	[4]
Sirolimus + Ifosfamide	DCWW0MZ	Sirolimus	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Sirolimus + Ifosfamide	DCRX0PF	Sirolimus	Adenocarcinoma (Cell Line: SW-620)	[5]
Sirolimus + Ifosfamide	DCK6IKW	Sirolimus	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Sorafenib + Ifosfamide	DCQUZ1P	Sorafenib	Adenocarcinoma (Cell Line: DU-145)	[3]
Sorafenib + Ifosfamide	DCW119E	Sorafenib	Adenocarcinoma (Cell Line: HT29)	[3]
Sorafenib + Ifosfamide	DCGAWOL	Sorafenib	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[3]
Sorafenib + Ifosfamide	DC1YYXO	Sorafenib	Amelanotic melanoma (Cell Line: M14)	[3]
Sorafenib + Ifosfamide	DCQHG9I	Sorafenib	Astrocytoma (Cell Line: U251)	[3]
Sorafenib + Ifosfamide	DC54GUG	Sorafenib	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[3]
Sorafenib + Ifosfamide	DCMPMMC	Sorafenib	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
Sorafenib + Ifosfamide	DCRY6KV	Sorafenib	Cutaneous melanoma (Cell Line: SK-MEL-28)	[3]
Sorafenib + Ifosfamide	DC2YBAY	Sorafenib	Lung adenocarcinoma (Cell Line: HOP-62)	[3]
Sorafenib + Ifosfamide	DCUWO09	Sorafenib	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[3]
Sorafenib + Ifosfamide	DCAU2GZ	Sorafenib	Lung adenocarcinoma (Cell Line: NCI-H522)	[3]
Sorafenib + Ifosfamide	DCS1GO4	Sorafenib	Melanoma (Cell Line: SK-MEL-2)	[3]
Sorafenib + Ifosfamide	DC4YAVH	Sorafenib	Melanoma (Cell Line: UACC-257)	[3]
Sorafenib + Ifosfamide	DCY7Y44	Sorafenib	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[3]
Sorafenib + Ifosfamide	DCNUSBV	Sorafenib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
Sorafenib + Ifosfamide	DCF0MYT	Sorafenib	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Sorafenib + Ifosfamide	DCUI0XG	Sorafenib	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
SY-1425 + Ifosfamide	DCWCQ26	SY-1425	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
SY-1425 + Ifosfamide	DC98KZP	SY-1425	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
TEM + Ifosfamide	DC9GTJV	TEM	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[3]
TEM + Ifosfamide	DCFTB6I	TEM	Chronic myelogenous leukemia (Cell Line: K-562)	[3]
TEM + Ifosfamide	DC5CKJP	TEM	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
TEM + Ifosfamide	DCNN149	TEM	Adenocarcinoma (Cell Line: DU-145)	[5]
TEM + Ifosfamide	DC6AX9H	TEM	Adenocarcinoma (Cell Line: HCT116)	[5]
TEM + Ifosfamide	DCK5VOV	TEM	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
TEM + Ifosfamide	DC3RAQH	TEM	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
TEM + Ifosfamide	DC8HHYB	TEM	Melanoma (Cell Line: UACC-257)	[5]
TEM + Ifosfamide	DCLTF24	TEM	Melanoma (Cell Line: SK-MEL-2)	[5]
TEM + Ifosfamide	DCGBAII	TEM	Prostate carcinoma (Cell Line: PC-3)	[5]
Terameprocol + Ifosfamide	DCC6J52	Terameprocol	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[3]
Terameprocol + Ifosfamide	DCM9N2R	Terameprocol	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Terameprocol + Ifosfamide	DCRS9K4	Terameprocol	Colon carcinoma (Cell Line: KM12)	[4]
Terameprocol + Ifosfamide	DCJO8MN	Terameprocol	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Terameprocol + Ifosfamide	DCG9E3S	Terameprocol	Adenocarcinoma (Cell Line: DU-145)	[5]
Terameprocol + Ifosfamide	DCDYE5Z	Terameprocol	Adenocarcinoma (Cell Line: HT29)	[5]
Terameprocol + Ifosfamide	DC4BKAL	Terameprocol	Adenocarcinoma (Cell Line: HCT116)	[5]
Terameprocol + Ifosfamide	DC4G5IS	Terameprocol	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Terameprocol + Ifosfamide	DCFG0AX	Terameprocol	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
Terameprocol + Ifosfamide	DCTNE7S	Terameprocol	Malignant melanoma (Cell Line: UACC62)	[5]
Terameprocol + Ifosfamide	DC54HU0	Terameprocol	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Terameprocol + Ifosfamide	DCFEYMI	Terameprocol	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Terameprocol + Ifosfamide	DCVL3ST	Terameprocol	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Thioguanine + Ifosfamide	DCUQXFZ	Thioguanine	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Thioguanine + Ifosfamide	DCHJ131	Thioguanine	Adenocarcinoma (Cell Line: HCT116)	[5]
Topotecan + Ifosfamide	DCXHHRF	Topotecan	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Topotecan + Ifosfamide	DCFU837	Topotecan	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Topotecan + Ifosfamide	DCZK8SG	Topotecan	Glioma (Cell Line: SF-268)	[5]
Triapine + Ifosfamide	DC4LPBJ	Triapine	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Triapine + Ifosfamide	DCRXUX4	Triapine	Astrocytoma (Cell Line: U251)	[5]
Triapine + Ifosfamide	DC6YFG1	Triapine	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Triapine + Ifosfamide	DCHR16N	Triapine	Clear cell renal cell carcinoma (Cell Line: TK-10)	[5]
Triapine + Ifosfamide	DCX2R4J	Triapine	Glioma (Cell Line: SF-295)	[5]
Triapine + Ifosfamide	DCWYDS5	Triapine	Malignant melanoma (Cell Line: UACC62)	[5]
Trifluridine + Ifosfamide	DCSRRE1	Trifluridine	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[3]
Trifluridine + Ifosfamide	DC818ZI	Trifluridine	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[3]
Trifluridine + Ifosfamide	DC3NSWC	Trifluridine	Plasma cell myeloma (Cell Line: RPMI-8226)	[3]
Trifluridine + Ifosfamide	DC8MD73	Trifluridine	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Trifluridine + Ifosfamide	DCYCJI4	Trifluridine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Uracil mustard + Ifosfamide	DCA1T71	Uracil mustard	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[3]
Uracil mustard + Ifosfamide	DCB50L8	Uracil mustard	Adenocarcinoma (Cell Line: HCT116)	[5]
Valrubicin + Ifosfamide	DC4G6IK	Valrubicin	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
Vandetanib + Ifosfamide	DC7HL3J	Vandetanib	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
Vandetanib + Ifosfamide	DCMHOXJ	Vandetanib	Invasive ductal carcinoma (Cell Line: BT-549)	[4]
Vandetanib + Ifosfamide	DCF8HCF	Vandetanib	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Vandetanib + Ifosfamide	DCXA71B	Vandetanib	Glioma (Cell Line: SF-268)	[5]
Vandetanib + Ifosfamide	DCMLQPH	Vandetanib	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Vandetanib + Ifosfamide	DCS3ZJT	Vandetanib	Melanoma (Cell Line: SK-MEL-2)	[5]
Vandetanib + Ifosfamide	DCN8ZBY	Vandetanib	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Vemurafenib + Ifosfamide	DCQNTXV	Vemurafenib	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Vemurafenib + Ifosfamide	DCYS3NL	Vemurafenib	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Vemurafenib + Ifosfamide	DCMBIZX	Vemurafenib	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Vemurafenib + Ifosfamide	DCELYBC	Vemurafenib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Vemurafenib + Ifosfamide	DC8WZSH	Vemurafenib	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Vincristine + Ifosfamide	DC1ZOB1	Vincristine	Adenocarcinoma (Cell Line: DU-145)	[3]
Vincristine + Ifosfamide	DCL1W2O	Vincristine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[3]
Vincristine + Ifosfamide	DCVZY9D	Vincristine	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Vincristine + Ifosfamide	DCUCR0P	Vincristine	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[3]
Vincristine + Ifosfamide	DCX9H0R	Vincristine	Prostate carcinoma (Cell Line: PC-3)	[3]
Vincristine + Ifosfamide	DC7055V	Vincristine	Renal cell carcinoma (Cell Line: SN12C)	[3]
Vincristine + Ifosfamide	DCFJLDU	Vincristine	Colon adenocarcinoma (Cell Line: COLO 205)	[4]
Vincristine + Ifosfamide	DCFUQXN	Vincristine	Invasive ductal carcinoma (Cell Line: HS 578T)	[4]
Vincristine + Ifosfamide	DC38UEZ	Vincristine	Invasive ductal carcinoma (Cell Line: T-47D)	[4]
Vinflunine + Ifosfamide	DCVF7UE	Vinflunine	Clear cell renal cell carcinoma (Cell Line: TK-10)	[3]
Vinflunine + Ifosfamide	DCAXKLY	Vinflunine	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[4]
Vinflunine + Ifosfamide	DCNE9UF	Vinflunine	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Vinflunine + Ifosfamide	DCAEGYJ	Vinflunine	Adenocarcinoma (Cell Line: SW-620)	[5]
Vinflunine + Ifosfamide	DCLSHFL	Vinflunine	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Vinflunine + Ifosfamide	DCJ6OAB	Vinflunine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Vinflunine + Ifosfamide	DCLHZQI	Vinflunine	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Vinflunine + Ifosfamide	DC47984	Vinflunine	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Vinflunine + Ifosfamide	DCFTX5S	Vinflunine	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Vinflunine + Ifosfamide	DCNCAWY	Vinflunine	Melanoma (Cell Line: MALME-3M)	[5]
Vinflunine + Ifosfamide	DC8F3FA	Vinflunine	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Vinflunine + Ifosfamide	DCGF0J7	Vinflunine	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Vinflunine + Ifosfamide	DCQIS4B	Vinflunine	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Vismodegib + Ifosfamide	DCW5VNX	Vismodegib	Glioma (Cell Line: SF-268)	[5]
Vismodegib + Ifosfamide	DCIYZ83	Vismodegib	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Vismodegib + Ifosfamide	DCLPQY5	Vismodegib	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 441 DrugCom(s)

17 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dactinomycin + Ifosfamide	DCCO9HX	Dactinomycin	Rhabdomyosarcoma	[6]
Dactinomycin + Ifosfamide	DCHFR1L	Dactinomycin	Rhabdomyosarcoma	[6]
Ifosfamide + Vinorelbine	DC450A4	Vinorelbine	Lymphoma	[7]
Ifosfamide + Zoledronate	DC9WUO6	Zoledronate	Osteosarcoma	[8]
Ifosfamide + Azathioprine	DCNSXSY	Azathioprine	Inflammatory Bowel Diseases	[9]
Ifosfamide + Etoposide	DC44WIJ	Etoposide	Adult Nasal Type Extranodal NK/T-cell Lymphoma	[10]
Ifosfamide + Aldoxorubicin	DCEDMNP	Aldoxorubicin	Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma	[11]
Ifosfamide + Etoposide	DC5UYFN	Etoposide	Cancer	[12]
Ifosfamide + Pazopanib	DC7YBSY	Pazopanib	Non-rhabdomyosarcoma	[13]
Ifosfamide + Carboplatin	DCLCDE1	Carboplatin	Solid Tumors	[14]
Ifosfamide + Fludarabine	DCBQ36A	Fludarabine	Acute Myeloid Leukemia	[15]
Ifosfamide + Famitinib	DCFWIE1	Famitinib	Effect of Drugs	[16]
Selinexor + Ifosfamide	DCNHDKM	Selinexor	Non-rhabdomyosarcoma	[13]
Cyclophosphamide + Ifosfamide	DCPUEJO	Cyclophosphamide	Sarcoma	[17]
Ifosfamide + Etoposide	DCQUKV7	Etoposide	Lymphoma	[18]
Ifosfamide + Bortezomib	DCG2D6V	Bortezomib	Adult Lymphocyte Depletion Hodgkin Lymphoma	[19]
Ifosfamide + Etoposide	DCTFJPR	Etoposide	Recurrent Nasopharynx Carcinoma	[20]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 DrugCom(s)

References

1	Ifosfamide FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7201).
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6	ClinicalTrials.gov (NCT04625907) FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
7	ClinicalTrials.gov (NCT00006760) Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
8	ClinicalTrials.gov (NCT00691236) Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
9	ClinicalTrials.gov (NCT04761952) N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease
10	ClinicalTrials.gov (NCT00601718) Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
11	ClinicalTrials.gov (NCT02235701) Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
12	ClinicalTrials.gov (NCT00003597) Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
13	ClinicalTrials.gov (NCT06239272) NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
14	ClinicalTrials.gov (NCT00502892) Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors
15	ClinicalTrials.gov (NCT04167696) Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1). U.S. National Institutes of Health.
16	ClinicalTrials.gov (NCT04044378) Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
17	ClinicalTrials.gov (NCT00072280) Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
18	ClinicalTrials.gov (NCT00006373) Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
19	ClinicalTrials.gov (NCT00381940) Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
20	ClinicalTrials.gov (NCT02137096) Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma